Drug Profile
Research programme: monoclonal antibody therapeutics - Human monoclonal international/Eisai Inc
Latest Information Update: 23 Jan 2020
Price :
$50
*
At a glance
- Originator Human Monoclonals International
- Developer Human Monoclonals International; Morphotek
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 11 Mar 2008 Preclinical trials in Cancer in USA (Parenteral)